African-Led Drug Discovery: Kelly Chibale’s Quest to Tackle Global Diseases

The hunt for new medicines is often associated with labs in North America, Europe, and Asia. But a pioneering scientist in South Africa is challenging that paradigm, leading a groundbreaking effort to discover and develop drugs tailored to the unique health needs of the African continent and beyond. Professor Kelly Chibale, founder of the Holistic Drug Discovery and Development (H3D) Centre at the University of Cape Town, is at the forefront of this revolution.

A Return to Roots and a Vision for African Science

After pursuing graduate studies and research in the U.K. And U.S., Professor Chibale felt a strong calling to return to Africa. He recognized a critical gap: although the pharmaceutical industry flourished in wealthier nations, Africa struggled with its own health challenges and a lack of local drug discovery infrastructure. This realization motivated him to establish the H3D Centre in 2010, a facility equipped for the entire drug discovery process.

The H3D Centre: A Comprehensive Approach to Drug Discovery

The H3D Centre is a rare facility in Africa, offering a complete pipeline for drug discovery and development. Researchers at the center utilize advanced technologies, including robotics, to screen vast libraries of molecules for potential therapeutic effects against diseases like malaria, tuberculosis, and antimicrobial resistance. The process involves identifying molecules that selectively kill pathogens without harming healthy cells, then refining those molecules to maximize their potency.

A First for Africa: Clinical Trials and Beyond

The H3D Centre’s approach led to a promising new malaria drug that entered clinical trials in South Africa and Ethiopia over a decade ago. This marked the first time an Africa-led initiative had taken a drug discovery project from the lab all the way to human clinical trials. While safety concerns identified in rat studies ultimately halted further development of that specific drug, the achievement demonstrated the potential of African-led research.

Addressing Genetic Diversity in Drug Development

Professor Chibale emphasizes the importance of considering Africa’s unique genetic diversity when developing new medicines. He notes that Africa is the most genetically diverse continent on Earth, and different subpopulations may metabolize drugs differently. To address this, the H3D Centre is working to obtain liver samples from diverse African populations to accurately determine appropriate drug dosages and ensure efficacy and safety.

Recognized Leadership and Global Impact

Professor Chibale’s contributions to drug discovery have garnered international recognition. He holds the Neville Isdell Chair in African-centric Drug Discovery & Development at the University of Cape Town and is a Full Member of the UCT Institute of Infectious Disease & Molecular Medicine. In 2025, he was elected to the United States National Academy of Sciences and selected as an American Society of Tropical Medicine and Hygiene (ASTMH) Distinguished International Fellow. He was also inducted as an International Member of the US National Academy of Medicine in 2024.

The Future of Drug Discovery in Africa

Professor Chibale’s work is inspiring a new generation of African scientists and paving the way for a more equitable and effective approach to global health. By building capacity within Africa, he aims to retain talent, address local health priorities, and ultimately improve the lives of millions. His vision is a testament to the power of scientific innovation driven by a deep commitment to the well-being of the African continent.